Now published in the 2018 Journal of Diabetes, research confirms some of the recently noted benefits of mild hyperbaric oxygen (m-HBOT) therapy for diabetics. Specifically, in lowering fasting and non-fasting glucose, HbA1c, and triglyceride levels; all of which are important markers leading to advanced disease states associated with this diabetes. Researchers also focused on skeletal muscle activity and fibers, and found that m-HBOT was able to help the muscle’s natural ability to use oxygen (which is typically compromised in diabetics). By helping to sensitize sugar metabolism and oxygen use within the skeletal muscles, m-HBOT can provide a significant benefit for people with diabetes. It should be noted however, that this protocol provided rats with m-HBOT daily (3 hours per day) for 22 consecutive weeks (about 5 months). <view study>